Intestinal bacteria butyribacterintestini and application thereof

Patent metadata

Field	Value
Publication number	US-2018339034-A1
Application number	US-201615755926-A
Country	US
Kind code	A1
Filing date	Mar 21, 2016
Priority date	Aug 27, 2015
Publication date	Nov 29, 2018
Grant date	—

Abstract

Provided is an application of Butyribacter intestini in the treatment and prevention of obesity and obesity-related diseases. Also provided is a composition for the treatment and prevention of obesity and obesity-related diseases.

First claim

1 - 10 . (canceled)

11 . A composition which comprises: (a) a safe and effective amount of Clostridium butylicum and/or metabolites thereof, wherein the Clostridium butylicum is Butyribacter intestini ; and (b) a food acceptable carrier or a pharmaceutically acceptable carrier.

12 . The composition of claim 11 , wherein the Clostridium butylicum is Butyribacter intestini TF01-11 with a deposit number of CGMCC 10984.

13 . The composition of claim 11 , wherein the composition comprises 1×10-1×10 20 cfu/mL or cfu/g of Butyribacter intestini TF01-11, based on total volume or total weight of the composition.

14 . The composition of claim 13 , wherein the composition comprises 1×10 4 -1×10 15 cfu/mL or cfu/g of Butyribacter intestini TF01-11, based on total volume or total weight of the composition.

15 . The composition of claim 11 , wherein the composition further comprises other probiotics and/or prebiotics.

16 . A method of treatment which comprises a step of: administrating a Clostridium butylicum or a composition comprising the Clostridium butylicum to a subject in need, wherein the Clostridium butylicum is Butyribacter intestini , and the treatment is for any of the group consisting of:
(a) preventing and/or treating obesity; (b) reducing weight and/or blood lipid; (c) preventing and/or treating a cardiovascular disease; (d) preventing and/or treating diabetes; (e) reducing level of monocyte chemotactic protein (MCP-1) in mammals; and (f) improving leptin resistance and increasing sensitivity to leptin in vivo.

17 . The method of claim 16 , wherein the Clostridium butylicum is Butyribacter intestini TF01-11 with a deposit number of CGMCC 10984.7.

18 . A Clostridium butylicum which is Butyribacter intestini.

19 . The Clostridium butylicum of claim 18 , wherein the Clostridium butylicum is Butyribacter intestini TF01-11 with a deposit number of CGMCC 10984.

20 . A production method which comprises the following steps:
(a) under a condition suitable for culturing, cultivating a Clostridium butylicum , thereby obtaining a culture product; (b) optionally, isolating Clostridium butylicum bacteria cells and/or metabolites thereof from the culture product; and (c) optionally, mixing the obtained Clostridium butylicum bacteria cells and/or their metabolites isolated in the previous step with a food-acceptable carrier or pharmaceutically acceptable carrier, thereby preparing a composition, wherein the Clostridium butylicum is Butyribacter intestini.

Assignees

• Bgi Shenzhen

Inventors

• Feng Qiang
• Xue Wenbin
• Zou Yuanqiang
• Li Xiaoping
• Liu Chuan
• Li Xin

Classifications

• A61K39/08 Primary

  Clostridium, e.g. Clostridium tetani · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61K9/00

  Medicinal preparations characterised by special physical form {(nuclear magnetic resonance contrast preparations or magnetic resonance imaging contrast preparations A61K49/18; preparations containing radioactive substances A61K51/12)} · CPC title

• C12N1/20

  Bacteria; Culture media therefor · CPC title

• A61K35/741

  Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06) · CPC title